Emerging and Evolving Biomarkers: METex14
Nikoletta Sidiropoulos, MD
Anthony Snow, MD
This webinar is a recorded presentation of a live broadcast and includes the presentation, handout, and the audience QA.
The mesenchymal epithelial transition factor (MET) gene encodes a receptor tyrosine kinase. MET juxtamembrane (JM) splicing variants or exon 14 skipping variants result in loss of exon 14 containing the JM domain of MET. As this domain is a negative regulator of MET the net result is oncogenic. Targeted therapies have been shown to be effective therapeutic options in some clinical settings when this variant type is present. Data is well developed in non-small cell carcinomas of the lung and ongoing trials in other solid tumors are underway as these variants are variably present in multiple tumor types at frequencies of approximately 1-4%. The scientific background information, testing techniques, and clinical applications of this biomarker will be discussed.
- Describe the underlying molecular biology of METex14 mutations.
- Review technical approaches for the detection of METex14 mutations.
- Discuss the clinical relevance of METex14 mutations.
Recording Date: September 29, 2020
Duration: 1 hr
Level of Instruction: Basic
CME credit: 1.00 hour
CMLE credit: 1.00 hour
Last Day to Claim CE Credit: December 31, 2022
This webinar is part 3 of the Emerging and Evolving Biomarkers Series.
This program has been supported through an educational grant from Bristol-Myers Squibb.
How to claim credit:
To earn CME/CMLE credit, all learners must watch the webinar and then complete the online survey.
AMA PRA Category 1 Credit(s)™
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of American Society for Clinical Pathology (ASCP) and Association for Molecular Pathology (AMP). The American Society for Clinical Pathology (ASCP) is accredited by the ACCME to provide continuing medical education for physicians.
The ASCP designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
This continuing medical laboratory education activity is recognized by the American Society for Clinical Pathology for 1.0 hours of CMLE credit. ASCP CMLE credit hours are acceptable for the ASCP Board of Certification (BOC) Certification Maintenance Program (CMP). CMLE credit hours meet the continuing education requirements for the ASCP Board of Certification Credential Maintenance Program (CMP) and state relicensure requirements for laboratory personnel. Participants should claim only the credit commensurate with the extent of their participation in the activity.
AMP is pleased to collaborate in the Immunotherapy Collaborative of Oncology Networked Communities, IC-ONC. IC-ONC is a global information network in which multidisciplinary healthcare providers, responsible for treating patients with cancer, are connected via education.
Please be sure to visit www.ic-onc.org to learn more about the collaborative and all it has to offer.
Note: Members of AMP can access many of the webinars at no cost or a deep discount. Join the AMP Family!
All sales are final. No refunds will be issued.
No digital files may be reproduced or transmitted in any form, by any means, electronic or mechanical. By purchasing a product, you agree to not share any of the course materials, including videos, downloadable slide presentations, outlines, manuscripts, etc. without explicit and written permission from AMP.